ECOR electroCore

electroCore Extends VA Contract for Five Years

electroCore Extends VA Contract for Five Years

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030.

“Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veterans,” commented Dan Goldberger, Chief Executive Officer of electroCore. “VA Hospital revenue accelerated in February and March, after modest slowing in January 2025, reflecting continued demand for this drug-free method for addressing migraine headaches.”

Mr. Goldberger continued, “On March 3, 2025, the VA terminated 585 non-mission critical or duplicative contracts following review by the new administration. This award of a new, five-year contract following such an audit further validates the value we provide the VA system and our veterans. We are greatly appreciative of the support we received during this two-year process from our FSS contract officer in ensuring our veterans have access to our non-opioid pain solution.” For more information regarding review and termination of VA contracts by the new administration, visit .

The new contract has a five-year term and contains customary revisions, including prompt pay discounts and volume rebates on revenues greater than $10 million in a calendar year. We will continue to operate under the current contract until June 15, 2025, at which time the new 5 year contract will become effective.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The Company is focused on commercializing medical devices for managing and treating certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects through the new FSS contract and availability to FSS eligible entities or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at

Contact:

ECOR Investor Relations

(973) 302-9253



EN
31/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effe...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Am...

 PRESS RELEASE

electroCore to Participate at the Planet MicroCap Showcase

electroCore to Participate at the Planet MicroCap Showcase ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged...

 PRESS RELEASE

electroCore Named One of The Americas’ Fastest Growing Companies by th...

electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors. This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the year...

 PRESS RELEASE

electroCore to Participate at the Needham Virtual Healthcare Conferenc...

electroCore to Participate at the Needham Virtual Healthcare Conference ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025. Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day. DATE: April 10, 2025TIME: 2:15 p.m. ETWEBCAST: A live audio webcast...

 PRESS RELEASE

electroCore Extends VA Contract for Five Years

electroCore Extends VA Contract for Five Years ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. “Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch